A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
Conditions
- Diabetes
- Diabetes Mellitus, Type 1
Interventions
- DRUG: Faster-acting insulin aspart
- DRUG: insulin aspart
Sponsor
Novo Nordisk A/S